Assuntos
Regulação da Expressão Gênica , Antígenos HLA-DR/genética , Transtornos Linfoproliferativos/imunologia , Mesoderma/patologia , Células Estromais/patologia , Antígenos CD/análise , Antígenos de Histocompatibilidade Classe I/análise , Humanos , Transtornos Linfoproliferativos/genética , Mesoderma/imunologia , Células Estromais/imunologiaRESUMO
An allogeneic irradiated RCC cell line, engineered to produce IL-2 (ACHN-IL-2), admixed with autologous metastatic formalin-treated tumour cells, was used to vaccinate ten MRCC patients in progression of disease in spite of IL-2 immunotherapy. The cells were administered subcutaneously and/or intra-tumourally. Sixty-four MRCC patients in progressive disease, not treated by vaccination but receiving similar IL-2 immunotherapy, were considered as the control group. Patients received 4-16 injections (mean 9 +/- 4), containing an average of 10.6 x 10(7) +/- 7.7 x 10(7) ACHN-IL-2-transfected cells (a minimum of 4 x 10(7), and a maximum of 31 x 10(7)). Four patients also received intra-tumour injections. Vaccination was administered during 30-418 days, and the follow-up continued for 649 +/- 353 days (190-1342). Throughout this period, the patients continued receiving the previously set immunotherapy treatment. No adverse side effects related to the treatment were observed. One complete and one partial tumour response were observed, as well as two stable and one no-relapse disease. All but one patient died. Responding patients resumed progression in 4-11 months and died 18 and 36 months after beginning the vaccine therapy. In spite of the small number of treated patients, Wilcoxon's test showed a significant (P < 0.05) improvement of the survival in the vaccinated group compared to that of the control. The described vaccination protocol seems safe, devoid of adverse side effects and promising. It warrants further investigation.
Assuntos
Neoplasias Renais/genética , Neoplasias Renais/terapia , Idoso , Vacinas Anticâncer/imunologia , Feminino , Técnicas de Transferência de Genes , Humanos , Imunoterapia Adotiva , Interleucina-2 , Neoplasias Renais/secundário , Masculino , Pessoa de Meia-Idade , Células Tumorais CultivadasRESUMO
Exposure to diisocyanates is recognized as a leading cause of occupational asthma. Occupational asthma induced by isocyanates shares many characteristics with immunoglobulin E (IgE)-mediated asthma: in both, the responsible agent is known, and the clinical presentation, response to inhalation challenge in the laboratory, and response to antiasthma drugs are similar. Although asthma mediated by an IgE mechanism occurs in atopic subjects, occupational asthma induced by isocyanates occurs mostly in nonatopic asthmatics, and an IgE-mediated mechanism has not been consistently demonstrated. However, activated T lymphocytes, methacromatic cells, and eosinophils are increased in the bronchial mucosa of allergic and nonallergic asthmatics and subjects with occupational asthma induced by isocyanates, suggesting similar, probably immunologically mediated mechanisms for both nonoccupational and occupational asthma. Occupational asthma occurs in up to 5-10% of the exposed subjects. Evaluation of major histocompatibility complex (MHC) class II genes in exposed subjects who develop toluene diisocyanate (TDI) asthma has shown a negative association with HLA-DQB1*0501 and a positive association with HLA-DQB1*0503 alleles. In addition, a high proportion of TDI asthmatics express the HLA-DQB1*0503-associated aspartic acid at residue 57, suggesting that HLA-DQ may have a key role in conferring susceptibility. Thus, asthma induced by the low-molecular-weight agent TDI may result from an immunologic reaction due to the interaction of genetic susceptibility with exposure in the workplace.
Assuntos
Asma/induzido quimicamente , Antígenos de Histocompatibilidade Classe II , Hipersensibilidade Imediata/imunologia , Isocianatos/efeitos adversos , Doenças Profissionais/induzido quimicamente , Anticorpos/imunologia , Asma/genética , Asma/imunologia , Antígenos de Histocompatibilidade Classe II/imunologia , Humanos , Imunoglobulina E/imunologia , Doenças Profissionais/genética , Doenças Profissionais/imunologiaRESUMO
Forty-four patients suffering from genital (22) and labial (22) herpes were orally treated with HSV-1/2-specific transfer factor (TF). TF was obtained by in vitro replication of a HSV-1/2-specific bovine dialysable lymphocyte extract. Treatment was administered bi-weekly the first 2 weeks, and then weekly for 6 months, most patients received 2-3 courses. The total observation period for all patients before treatment was 26,660 days, with 544 relapses, and a relapse index of 61.2, whereas the cumulative observation period during and after treatment was 16,945 days, with a total of 121 relapsing episodes and a cumulative RI of 21.4 (P < 0.0001). Results were equally significant when the 2 groups of patients (labial and genital) were considered separately. These observations confirm previous results obtained with bovine HSV-specific TF, and warrant further studies to establish HSV-specific TF as a choice of treatment for preventing herpes recurrences.
Assuntos
Herpes Genital/prevenção & controle , Herpes Labial/prevenção & controle , Herpesvirus Humano 1/imunologia , Herpesvirus Humano 2/imunologia , Fator de Transferência/uso terapêutico , Síndrome da Imunodeficiência Adquirida/imunologia , Síndrome da Imunodeficiência Adquirida/virologia , Administração Oral , Adolescente , Adulto , Idoso , Animais , Bovinos , Feminino , Herpes Genital/imunologia , Herpes Labial/imunologia , Humanos , Imunidade Celular/efeitos dos fármacos , Imunidade Celular/imunologia , Linfócitos/química , Linfócitos/imunologia , Masculino , Pessoa de Meia-Idade , Sensibilidade e Especificidade , Fator de Transferência/imunologiaAssuntos
Asma/induzido quimicamente , Antígenos HLA-DQ/genética , Tolueno 2,4-Di-Isocianato/efeitos adversos , Alelos , Sequência de Aminoácidos , Asma/genética , Asma/imunologia , Suscetibilidade a Doenças/imunologia , Predisposição Genética para Doença , Antígenos HLA-DQ/química , Cadeias beta de HLA-DQ , Humanos , Doenças Profissionais/induzido quimicamente , Doenças Profissionais/genética , Doenças Profissionais/imunologiaRESUMO
Cytoplasmic protein kinase C (PKC) has been studied in phytohemagglutinin (PHA) activated peripheral blood mononuclear cells (PBMC) and macrophage depleted E+ cell culture. Within 10' after contemporanous addition of PHA and anti HLA class I monoclonal antibody 01.65 (MoAb) PKC is depleted in both cell types. Enzyme activity recovers in the following hours however at 72 hours is at control values in E+ cultures while in PBMC cultures it is still depleted at 68% of the control. Anti HLA class I MoAb induced tritiated lymidine (3H-TdR) incorporation inhibition appears to be related to low levels of PKC activity.
Assuntos
Anticorpos Monoclonais , Antígenos de Histocompatibilidade Classe I/imunologia , Ativação Linfocitária , Proteína Quinase C/metabolismo , Linfócitos T/enzimologia , Células Cultivadas , Replicação do DNA , Humanos , Cinética , Proteína Quinase C/imunologia , Formação de Roseta , Linfócitos T/citologia , Linfócitos T/imunologiaAssuntos
Anticorpos Monoclonais , Antígenos HLA/imunologia , Linfócitos/efeitos dos fármacos , Receptores Mitogênicos/metabolismo , Cálcio/metabolismo , Divisão Celular/efeitos dos fármacos , Humanos , Hidrólise , Linfócitos/imunologia , Linfócitos/metabolismo , Fosfatidilinositóis/metabolismo , Fito-Hemaglutininas/farmacologia , Timidina/metabolismoRESUMO
We have studied the effect of the two antibodies, MF 25.1 and GF 26.7.3, on leucocyte function: these antibodies did not mimic the effect of cellular stimuli, but the pre-treatment of neutrophils with MF 25.1 and GF 26.7.3 modulated several cell activities. Both antibodies significantly reduced superoxide anion production in response to various stimuli. Despite similar cellular response MF 25.1 and GF 26.7.3 bound to different antigenic determinants, as shown both by immunoblotting studies and by treating neutrophils first with GF 26.7.3 and subsequently with MF 25.1, and vice-versa; the inhibition of superoxide production corresponded, in fact, to the total of that seen for each antibody. Moreover, in the absence of attractant, measures of locomotion of neutrophils treated with monoclonal antibody showed that 43% of the subjects responded to antibody binding by twofold activation of spontaneous movement. Chemotaxis and lysosomal enzyme release were not affected by antibody treatment.
Assuntos
Anticorpos Monoclonais , Neutrófilos/imunologia , Movimento Celular , Quimiotaxia de Leucócito , Epitopos , Glucuronidase/metabolismo , Humanos , Técnicas In Vitro , Muramidase/metabolismo , Neutrófilos/fisiologia , Superóxidos/metabolismoRESUMO
Anti HLA Class I Monoclonal Antibody depletes Protein Kinase C (PKC) to 20% of control value in PHA activated human T cells. The effect is reversible: in 24 hours the enzymatic activity returns to 58% of control value. Removal of antibody from the culture medium increases the rate of recovery. Implications of this finding for the modulation by HLA Class I antigens of the proliferative response of T cells to lectins are discussed.
Assuntos
Anticorpos Monoclonais , Antígenos HLA/imunologia , Ativação Linfocitária , Fito-Hemaglutininas/farmacologia , Proteína Quinase C/metabolismo , Linfócitos T/enzimologia , Adulto , Células Cultivadas , Humanos , Linfócitos T/efeitos dos fármacosRESUMO
Monoclonal antibodies (mAbs) against cell surface antigens and receptors are instrumental in defining specific membrane markers. mAbs GF 26.7.3 and MF 25.1 against human neutrophils modulated the activation mechanism of superoxide anion production induced by formyl-peptide and PMA in all subject. However, treatment with mAb MF 25.1 of neutrophils from patients with rheumatoid arthritis did not have any effect. This may suggest that the antigen which MF 25.1 binds is absent in rheumatoid conditions. This confirms our previous data showing that defective expression of membrane components is associated with neutrophil dysfunction.
Assuntos
Anticorpos Monoclonais , Antígenos de Superfície/análise , Artrite Reumatoide/imunologia , Neutrófilos/imunologia , Humanos , N-Formilmetionina Leucil-Fenilalanina/farmacologia , Neutrófilos/efeitos dos fármacos , Superóxidos/metabolismo , Acetato de Tetradecanoilforbol/farmacologiaRESUMO
Duchenne muscular dystrophy is a severe inherited disease. The pathogenesis is unknown. Duchenne dystrophy is characterized by a large number of membrane abnormalities, which are manifested by a leakage of muscle enzymes, such as creatine kinase (CK), and a reduction in cap formation in lymphocytes. In the present study serum CK and percentage lymphocyte capping in 8 patients with progressive muscular dystrophy, 6 with different myopathies and normal controls are investigated. Reduced antibody-induced redistribution of membrane antigens of B and T lymphocytes and high serum CK activity is found in boys with Duchenne dystrophy if compared with normal subjects and no correlation exists between the two parameters. Our data indicate that the determination of fetal serum CK activity associated with fetal lymphocyte capping may have diagnostic value in antenatal detection of Duchenne dystrophy.